Adalimumab/golimumab/infliximab

Abstract

Lack of efficacy, infusion reaction and drug eruption: 21 case reports In a retrospective study involving 123 patients with refractory ulcerative colitis (UC) treated between July 2010 and August 2018 across various hospitals in Japan, 21 patients [ages and sexes not stated] were described who exhibited lack of efficacy (18 patients), developed infusion reactions (2 patients) or developed eruption (1 patient) during treatment with adalimumab, golimumab or infliximab [durations of treatments to reactions onsets and outcomes not stated]. The patients with active UC started receiving treatment with infliximab infusions 5 mg/kg at weeks 0, 2, and 6, which was followed by maintenance IV infusions infliximab 5 mg/kg injections every 8 weeks, SC adalimumab 160mg at week 0 and 80mg at week 2, which was followed by maintenance SC 40mg doses every other week or SC golimumab 200mg at week 0 and 100mg at week 2, which was followed by maintenance SC 100mg doses every 4 weeks. Concomitantly, all patients received mesalazine [5-ASA] and unspecified corticosteroids. Out of the 21 patients, 18 patients exhibited lack of efficacy with the first therapies (10 patients with infliximab and 8 patients with adalimumab), two patients developed infusion reactions with infliximab and one patient developed eruptions during treatment with adalimumab. Out of these 18 patients (who exhibited LOE), 10 patients exhibited LOE with first therapy infliximab, and the treatment was changed from to adalimumab in 7 patients (one of these patient again exhibited LOE to adalimumab as well) and to golimumab in 3 patients. The remaining 8 patients exhibited LOE to first therapy adalimumab, and the treatment was changed to infliximab in 7 patients (three of these patients again exhibited LOE to infliximab as well) and to golimumab in 1 patient who again exhibited LOE to the golimumab therapy as well. In the two patients who developed infusion reactions with infliximab, the treatment was changed to adalimumab (1 patient) and to golimumab (1 patient). Subsequently, both the patients achieved clinical remission. In the one patient who developed eruptions during treatment with adalimumab, the treatment was changed to golimumab. The patient subsequently achieved clinical remission.